-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Positive Sentiment Still Eludes Austar Lifesciences Limited (HKG:6118) Following 29% Share Price Slump
Positive Sentiment Still Eludes Austar Lifesciences Limited (HKG:6118) Following 29% Share Price Slump
The Austar Lifesciences Limited (HKG:6118) share price has fared very poorly over the last month, falling by a substantial 29%. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 94% loss during that time.
Although its price has dipped substantially, there still wouldn't be many who think Austar Lifesciences' price-to-earnings (or "P/E") ratio of 7.1x is worth a mention when the median P/E in Hong Kong is similar at about 9x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/E.
As an illustration, earnings have deteriorated at Austar Lifesciences over the last year, which is not ideal at all. One possibility is that the P/E is moderate because investors think the company might still do enough to be in line with the broader market in the near future. If you like the company, you'd at least be hoping this is the case so that you could potentially pick up some stock while it's not quite in favour.
Check out our latest analysis for Austar Lifesciences
SEHK:6118 Price Based on Past Earnings September 19th 2022 Want the full picture on earnings, revenue and cash flow for the company? Then our free report on Austar Lifesciences will help you shine a light on its historical performance.Does Growth Match The P/E?
Austar Lifesciences' P/E ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the market.
Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 56%. However, a few very strong years before that means that it was still able to grow EPS by an impressive 1,216% in total over the last three years. Although it's been a bumpy ride, it's still fair to say the earnings growth recently has been more than adequate for the company.
This is in contrast to the rest of the market, which is expected to grow by 20% over the next year, materially lower than the company's recent medium-term annualised growth rates.
With this information, we find it interesting that Austar Lifesciences is trading at a fairly similar P/E to the market. It may be that most investors are not convinced the company can maintain its recent growth rates.
The Key Takeaway
With its share price falling into a hole, the P/E for Austar Lifesciences looks quite average now. Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.
We've established that Austar Lifesciences currently trades on a lower than expected P/E since its recent three-year growth is higher than the wider market forecast. There could be some unobserved threats to earnings preventing the P/E ratio from matching this positive performance. At least the risk of a price drop looks to be subdued if recent medium-term earnings trends continue, but investors seem to think future earnings could see some volatility.
Having said that, be aware Austar Lifesciences is showing 2 warning signs in our investment analysis, and 1 of those makes us a bit uncomfortable.
You might be able to find a better investment than Austar Lifesciences. If you want a selection of possible candidates, check out this free list of interesting companies that trade on a P/E below 20x (but have proven they can grow earnings).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
这个奥星生命科学有限公司(HKG:6118)股价在过去一个月表现非常糟糕,大幅下跌29%。最近的下跌为股东们灾难性的12个月画上了句号,在此期间,他们坐拥94%的损失。
虽然其股价已大幅下跌,但在香港市盈率中值约为9倍的情况下,仍不会有很多人认为奥星生命科学7.1倍的市盈率(即市盈率)值得一提。然而,如果市盈率没有理性基础,投资者可能会忽视一个明显的机会或潜在的挫折。
举例来说,过去一年,奥星生命科学公司的收入一直在恶化,这根本不是理想的情况。一种可能性是,市盈率是温和的,因为投资者认为,该公司在不久的将来可能仍会采取足够的措施,与大盘保持一致。如果你喜欢这家公司,你至少会希望情况是这样的,这样你就可以在它不太受欢迎的时候买入一些股票。
查看我们对Austar生命科学的最新分析
联交所:6118基于过去收益的价格2022年9月19日想要了解公司的收益、收入和现金流的全貌吗?那么我们的免费金星生命科学的报告将帮助你了解它的历史表现。增长是否与市盈率匹配?
对于一家预计只会实现适度增长,而且重要的是表现与市场一致的公司来说,Austar Lifesciences的市盈率将是典型的。
首先回顾一下,该公司去年的每股收益增长并不是什么令人兴奋的事情,因为它公布了令人失望的下降56%。然而,在此之前的几年非常强劲,这意味着它仍然能够在过去三年中实现令人印象深刻的1216%的每股收益增长。尽管这是一段坎坷的旅程,但公平地说,最近的收益增长对公司来说已经绰绰有余。
这与其他市场形成对比,后者预计明年将增长20%,大大低于该公司最近的中期年化增长率。
有了这些信息,我们发现有趣的是,Austar Lifesciences的市盈率与市场相当相似。可能是大多数投资者不相信该公司能够保持最近的增长速度。
关键的外卖
随着其股价跌入低谷,奥星生命科学公司的市盈率现在看起来相当平均。仅仅用市盈率来决定你是否应该出售你的股票是不明智的,但它可以成为公司未来前景的实用指南。
我们已经确定,奥星生命科学目前的市盈率低于预期,因为它最近的三年增长高于更广泛的市场预测。可能存在一些未被察觉的盈利威胁,阻碍了市盈率与这一积极表现的匹配。至少,如果近期的中期盈利趋势持续下去,股价下跌的风险看起来会较低,但投资者似乎认为,未来的盈利可能会出现一些波动。
话虽如此,但请注意Austar生命科学公司正在显示两个警告信号在我们的投资分析中,其中之一让我们有点不舒服。
你也许能找到比Austar Lifesciences更好的投资。如果您想要选择可能的候选人,请查看以下内容免费令人感兴趣的市盈率低于20倍的公司名单(但已证明它们可以增加收益)。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧